BioLineRx Ltd.
BLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001498403
No open-market purchases or sales by BioLineRx Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $206.7K in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in BioLineRx Ltd. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q3 2025
- Shares held
- 47.8K
- +20.1K (+72.4%) vs. Q3 2025
- Total value
- $135.6K
- +$31.3K (+30.0%) vs. Q3 2025
- New holders
- 3
- 4 more added
- Sold out
- 3
- 2 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $206.7K |
| Q1 2026 | 13 | $45.2K |
| Q4 2025 | 14 | $135.6K |
| Q3 2025 | 14 | $104.3K |
| Q2 2025 | 17 | $302.1K |
| Q1 2025 | 12 | $28.0K |
| Q4 2024 | 32 | $435.9K |
| Q3 2024 | 32 | $1.34M |
| Q2 2024 | 31 | $2.42M |
| Q1 2024 | 28 | $1.47M |
| Q4 2023 | 29 | $1.75M |
| Q3 2023 | 29 | $2.46M |
| Q2 2023 | 26 | $1.97M |
| Q1 2023 | 20 | $2.91M |
| Q4 2022 | 18 | $3.37M |
| Q3 2022 | 28 | $10.3M |
| Q2 2022 | 28 | $1.36M |
| Q1 2022 | 26 | $1.99M |
| Q4 2021 | 30 | $5.09M |
| Q3 2021 | 30 | $6.69M |
| Q2 2021 | 30 | $4.01M |
| Q1 2021 | 29 | $13.5M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding BioLineRx Ltd.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 36,651 | $104.5K | 0.00% | +26,631+265.8% | Added |
| Rhumbline Advisers | 3,353 | $9.55K | 0.00% | +283+9.2% | Added |
| Citigroup Inc | 2,038 | $5.81K | 0.00% | +2,038 | New |
| UBS Group AG | 1,951 | $5.40K | 0.00% | −4,436−69.5% | Reduced |
| Wells Fargo & Company | 1,750 | $4.85K | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 1,500 | $4.16K | 0.00% | +1,500 | New |
| Nemes Rush Group LLC | 250 | $693 | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 107 | $296 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 100 | $277 | 0.00% | −5,853−98.3% | Reduced |
| Advisor Group Holdings, Inc. | 26 | $71 | 0.00% | +25+2,500.0% | Added |
| Rockefeller Capital Management L.P. | 12 | $33 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 10 | $28 | 0.00% | +8+400.0% | Added |
| Danske Bank A/S | 2 | $6 | 0.00% | 00.0% | Unchanged |
| Banque Cantonale Vaudoise | 1 | $0 | 0.00% | +1 | New |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −39−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −105−100.0% | Sold out |